J Rheum Dis 2020; 27(1): 4-21  
The Use of Biological Disease-modifying Antirheumatic Drugs for Inflammatory Arthritis in Korea: Results of a Korean Expert Consensus
Eun-Jung Park, M.D.1, Hyungjin Kim, M.D., Ph.D.2, Seung Min Jung, M.D., Ph.D.3, Yoon-Kyoung Sung, M.D., Ph.D.4, Han Joo Baek, M.D., Ph.D.5, Jisoo Lee, M.D., Ph.D.6
1Division of Rheumatology, Department of Medicine, National Medical Center, 2Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 3Division of Rheumatology, Department of Medicine, Yonsei University College of Medicine, 4Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, 5Division of Rheumatology, Department of Internal Medicine, Gachon University College of Medicine Gil Medical Center, Incheon, 6Division of Rheumatology, Department of Internal Medicine, Ewha Womans University College of Medicine, Seoul, Korea
Correspondence to: Jisoo Lee http://orcid.org/0000-0001-6279-7025
Division of Rheumatology, Department of Internal Medicine, Ewha Womans University College of Medicine, 1071 Anyangcheon-ro, Yangcheon-gu, Seoul 07985, Korea. E-mail:leejisoo@ewha.ac.kr
Han Joo Baek http://orcid.org/0000-0001-7558-052X
Division of Rheumatology, Department of Internal Medicine, Gachon University College of Medicine Gil Medical Center, 21 Namdong-daero 774beon-gil, Namdong-gu, Incheon 21565, Korea. E-mail:baekhj@gilhospital.com
Received: December 3, 2019; Revised: December 11, 2019; Accepted: December 11, 2019; Published online: January 1, 2020.
© Korean College of Rheumatology. All rights reserved.

This is a open Access article, which permits unrestricted non-commerical use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Biological disease-modifying antirheumatic drugs (bDMARDs) are highly effective agents for the treatment of inflammatory arthritis; however, they also possess a potential risk for serious infection. Recently, with the rapid expansion of the bDMARDs market in Korea, reports of serious adverse events related to the agents have also increased, necessitating guidance for the use of bDMARDs. Current work entitled, “Expert Consensus for the Use of bDMARDs Drugs for Inflammatory Arthritis in Korea,” is the first to describe the appropriate use of bDMARDs in the management of inflammatory arthritis in Korea, with an aim to provide guidance for the local medical community to improve the quality of clinical care. Twelve consensus statements regarding the use of bDMARDs for the management of rheumatoid arthritis and ankylosing spondylitis were generated. In this review, we provide detailed guidance on bDMARDs use based on expert consensus, including who should prescribe, the role of education, indications for use, and monitoring strategies for safety.
Keywords: Expert consensus, bDMARDs, Inflammatory arthritis, Rheumatoid arthritis, Ankylosing spondylitis


This Article

e-submission

Archives